Alnylam PharmaceuticalsSTU:DUL +0.31%66 Median PS Value is €954.82 as of Jun. 30, 2026, which is 100% below its 10-year median of 0.37. GuruFocus rates STU:DUL with a GF Score™ of 66/100 and a GF Value™ of €449.47 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 276 Biotechnology companies, Alnylam Pharmaceuticals ranks better than 83.33% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Alnylam Pharmaceuticals's Median PS Value or its related term are showing as below:
STU:DUL'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11 Med: 0.37 Max: 8.48
Current: 0.27
During the past 13 years, the highest Price to Median PS Value of Alnylam Pharmaceuticals was 8.48. The lowest was 0.11. And the median was 0.37.
STU:DUL's Price-to-Median-PS-Value is ranked better than 83.33% of 276
companies
in the Biotechnology industry
Industry Median: 0.63
vs STU:DUL: 0.27
Alnylam Pharmaceuticals (STU:DUL) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Alnylam Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
256.80
/
954.82
=
0.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Median PS Value Related Terms
Alnylam Pharmaceuticals Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:DUL vs RVMD, ONC, MRNA: Median PS Value Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 35.284.
Alnylam Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €27.061.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (STU:DUL) has a Median PS Value of €954.82 as of Jun. 30, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Alnylam Pharmaceuticals and its competitors. This is 257959% above median its historical median of 0.37. Over the past decade, Alnylam Pharmaceuticals' Median PS Value has ranged from 0.11 to 8.48. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #46 out of 276 companies in the Biotechnology industry, placing it in the top 16.7%.
Is Alnylam Pharmaceuticals' Median PS Value too high?
Alnylam Pharmaceuticals' current Median PS Value of €954.82 is 257959% above median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 8.48. Based on the distribution chart, Alnylam Pharmaceuticals ranks #46 out of 276 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alnylam Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Median PS Value compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #46 out of 276 companies for Median PS Value. This places Alnylam Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.63. Historically, Alnylam Pharmaceuticals' own Median PS Value has ranged from 0.11 to 8.48 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Median PS Value is €954.82, which is 257959% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (STU:DUL) is currently considered Significantly Undervalued. The stock's GF Value™ is €449.47, compared to a current price of €256.80 — trading 42.9% below its estimated fair value. The current Median PS Value is €954.82, which is 257959% above median its 10-year median of 0.37. Alnylam Pharmaceuticals' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Alnylam Pharmaceuticals (STU:DUL), the current Median PS Value is €954.82 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (STU:DUL) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of €256.80 is trading 42.9% below its estimated GF Value™ of €449.47.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for STU:DUL:
Median PS Value: €954.82 (257959% above median its 10-year median of 0.37)
GF Value™: €449.47 vs. price of €256.80 (42.9% below fair value)
No single metric tells the full story. See the STU:DUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
66GF Score
Get the complete analysis for STU:DUL
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:DUL has been successfully added to your 
